ak129
mAbexperimentalBi-specific
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 15, 2023 (NCT05645276)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- LAG3ANTAGONIST
lag3
- Programmed cell death 1 ligand 1ANTAGONIST
PDL1
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06943820 | Phase 1/Phase 2 (Phase 2) | May 21, 2025 | Akeso Pharmaceuticals, Inc. |
| NCT06642792 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2024 | Akeso Pharmaceuticals, Inc. |
| NCT06586294 | Phase 1/Phase 2 (Phase 2) | Sep 10, 2024 | Akeso Pharmaceuticals, Inc., Chinese Academy of Medical Sciences |
| NCT05645276 | Phase 1 | Jan 15, 2023 | Akeso Pharmaceuticals, Inc., Chinese Academy of Medical Sciences |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Akeso Pharmaceuticals, Inc. | For profit | 4 | 4 | 2 | 2023 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 0 | 2 | 2023 |
2 organizations
Page 1 / 1